AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BerGenBio

Share Issue/Capital Change Jun 21, 2019

3555_rns_2019-06-21_4e977674-1ab4-4d54-bbf6-edbf9657db78.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

BerGenBio ASA: Share capital increase

BerGenBio ASA: Share capital increase

Bergen, Norway, 21 June 2019 - Reference is made to the stock exchange notice

published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 13 June 2018 where

the Company announced that the board of directors of the Company had resolved to

increase the Company's share capital in connection with the private placement. A

total of 5,495,144 shares was issued at a subscription price of NOK 13.50 per

share.

The share capital increase has been duly registered in the Norwegian Register of

Business Enterprises. Following such registration, the Company's share capital

is NOK 6,044,659 divided into 60,446,590 shares, each with a nominal value of

NOK 0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

[email protected]

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are

not historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.